Cargando…

Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer

PURPOSE: Vascular endothelial growth factor (VEGF)-A, VEGF(165)b, interleukin (IL)-1β, and transforming growth factor (TGF)-β1 are known to influence tumor angiogenesis. Clinical implications of these cytokines need to be elucidated. MATERIALS AND METHODS: Using clinical data and baseline serum samp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Ji-Won, Koh, Youngil, Kim, Dong-Wan, Ahn, Yong-Oon, Kim, Tae Min, Han, Sae-Won, Oh, Do-Youn, Lee, Se-Hoon, Im, Seock-Ah, Kim, Tae-You, Heo, Dae Seog, Bang, Yung-Jue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893330/ https://www.ncbi.nlm.nih.gov/pubmed/24454005 http://dx.doi.org/10.4143/crt.2013.45.4.325

Ejemplares similares

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
por: Kim, Su-Jung, et al.
Publicado: (2010)

TGF-β Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells
por: Kang, Soyeong, et al.
Publicado: (2015)

Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer
por: Baek, Sun Kyung, et al.
Publicado: (2011)

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
por: Kim, Mi-Jung, et al.
Publicado: (2008)

NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations
por: PARK, EUNJU, et al.
Publicado: (2011)

Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
por: Ha, Hyerim, et al.
Publicado: (2016)

The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy
por: Choi, Younak, et al.
Publicado: (2016)

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index
por: Choi, Younak, et al.
Publicado: (2015)

Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX
por: Kim, Mi-Jung, et al.
Publicado: (2016)

Korean Cancer Patients’ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate
por: Lim, Yoojoo, et al.
Publicado: (2017)

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
por: Keam, Bhumsuk, et al.
Publicado: (2008)

More Accurate Prediction of Metastatic Pancreatic Cancer Patients’ Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity
por: Choi, Younak, et al.
Publicado: (2016)

A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer
por: Lee, Hyun Jung, et al.
Publicado: (2014)

Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2005)

The role of PET/CT in detection of gastric cancer recurrence
por: Sim, Sung Hoon, et al.
Publicado: (2009)

Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy
por: Cho, Kyoung-Min, et al.
Publicado: (2017)

Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer
por: Cho, Kyoung-Min, et al.
Publicado: (2016)

Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data
por: Lee, Kyung-Hun, et al.
Publicado: (2012)

CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
por: Lee, Dae-Won, et al.
Publicado: (2017)

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
por: Keam, Bhumsuk, et al.
Publicado: (2011)

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
por: Kim, Tae Min, et al.
Publicado: (2018)

Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma
por: Lee, Kyung-Hun, et al.
Publicado: (2015)

Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
por: Oh, Do-Youn, et al.
Publicado: (2015)

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
por: Rhee, Jiyoung, et al.
Publicado: (2008)

Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study
por: Choi, Younak, et al.
Publicado: (2016)

Adjuvant Chemotherapy in Microsatellite Instability–High Gastric Cancer
por: Kim, Jin Won, et al.
Publicado: (2020)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
por: Kim, Jin Won, et al.
Publicado: (2020)

Therapeutic implication of HER2 in advanced biliary tract cancer
por: Nam, Ah-Rong, et al.
Publicado: (2016)

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
por: Keam, Bhumsuk, et al.
Publicado: (2011)

A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
por: Lee, Dae-Won, et al.
Publicado: (2018)

Diagnostic performance of contrast enhanced CT and (18)F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection
por: Lee, Yun-Gyoo, et al.
Publicado: (2011)

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
por: Min, Ahrum, et al.
Publicado: (2015)

TRAF6 Mediates IL-1β/LPS-Induced Suppression of TGF-β Signaling through Its Interaction with the Type III TGF-β Receptor
por: Lim, Seunghwan, et al.
Publicado: (2012)

A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions
por: Kim, Tae-Yong, et al.
Publicado: (2014)

Prognostic Value of Splenic Artery Invasion in Patients Undergoing Adjuvant Chemoradiotherapy after Distal Pancreatectomy for Pancreatic Adenocarcinoma
por: Kim, Byoung Hyuck, et al.
Publicado: (2015)

Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer
por: Ha, Hye rim, et al.
Publicado: (2016)

Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients
por: Lee, Dae-Won, et al.
Publicado: (2015)

Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors
por: Kwon, Jeanny, et al.
Publicado: (2014)

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
por: Lee, Kyung-Hun, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_jg89cfca21eoegaqm455l31q47